Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: DRUG: Camrelizumab|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel
Sponsor: Aiping Shi